Literature DB >> 24321263

Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours.

Laurel T Bate-Eya1, Marli E Ebus1, Jan Koster1, Ilona J M den Hartog1, Danny A Zwijnenburg1, Linda Schild1, Ida van der Ploeg1, M Emmy M Dolman1, Huib N Caron2, Rogier Versteeg1, Jan J Molenaar3.   

Abstract

Recently protocols have been devised for the culturing of cell lines from fresh tumours under serum-free conditions in defined neural stem cell medium. These cells, frequently called tumour initiating cells (TICs) closely retained characteristics of the tumours of origin. We report the isolation of eight newly-derived neuroblastoma TICs from six primary neuroblastoma tumours and two bone marrow metastases. The primary tumours from which these TICs were generated have previously been fully typed by whole genome sequencing (WGS). Array comparative genomic hybridisation (aCGH) analysis showed that TIC lines retained essential characteristics of the primary tumours and exhibited typical neuroblastoma chromosomal aberrations such as MYCN amplification, gain of chromosome 17q and deletion of 1p36. Protein analysis showed expression for neuroblastoma markers MYCN, NCAM, CHGA, DBH and TH while haematopoietic markers CD19 and CD11b were absent. We analysed the growth characteristics and confirmed tumour-forming potential using sphere-forming assays, subcutaneous and orthotopic injection of these cells into immune-compromised mice. Affymetrix mRNA expression profiling of TIC line xenografts showed an expression pattern more closely mimicking primary tumours compared to xenografts from classical cell lines. This establishes that these neuroblastoma TICs cultured under serum-free conditions are relevant and useful neuroblastoma tumour models.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Neuroblastoma; Neuroblastoma TICs; Principal component analysis; Whole genome sequencing; aCGH

Mesh:

Substances:

Year:  2013        PMID: 24321263     DOI: 10.1016/j.ejca.2013.11.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  27 in total

1.  Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma.

Authors:  Sora Lee; Eric J Rellinger; Kwang Woon Kim; Brian T Craig; Carmelle V Romain; Jingbo Qiao; Dai H Chung
Journal:  Surgery       Date:  2015-06-09       Impact factor: 3.982

Review 2.  Origin and initiation mechanisms of neuroblastoma.

Authors:  Shoma Tsubota; Kenji Kadomatsu
Journal:  Cell Tissue Res       Date:  2018-02-14       Impact factor: 5.249

3.  Neuroblastoma is composed of two super-enhancer-associated differentiation states.

Authors:  Tim van Groningen; Jan Koster; Linda J Valentijn; Danny A Zwijnenburg; Nurdan Akogul; Nancy E Hasselt; Marloes Broekmans; Franciska Haneveld; Natalia E Nowakowska; Johannes Bras; Carel J M van Noesel; Aldo Jongejan; Antoine H van Kampen; Linda Koster; Frank Baas; Lianne van Dijk-Kerkhoven; Margriet Huizer-Smit; Maria C Lecca; Alvin Chan; Arjan Lakeman; Piet Molenaar; Richard Volckmann; Ellen M Westerhout; Mohamed Hamdi; Peter G van Sluis; Marli E Ebus; Jan J Molenaar; Godelieve A Tytgat; Bart A Westerman; Johan van Nes; Rogier Versteeg
Journal:  Nat Genet       Date:  2017-06-26       Impact factor: 38.330

4.  RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.

Authors:  Carolina Nunes; Lisa Depestel; Liselot Mus; Kaylee M Keller; Louis Delhaye; Amber Louwagie; Muhammad Rishfi; Alex Whale; Neesha Kara; Simon R Andrews; Filemon Dela Cruz; Daoqi You; Armaan Siddiquee; Camila Takeno Cologna; Sam De Craemer; Emmy Dolman; Christoph Bartenhagen; Fanny De Vloed; Ellen Sanders; Aline Eggermont; Sarah-Lee Bekaert; Wouter Van Loocke; Jan Willem Bek; Givani Dewyn; Siebe Loontiens; Gert Van Isterdael; Bieke Decaesteker; Laurentijn Tilleman; Filip Van Nieuwerburgh; Vanessa Vermeirssen; Christophe Van Neste; Bart Ghesquiere; Steven Goossens; Sven Eyckerman; Katleen De Preter; Matthias Fischer; Jon Houseley; Jan Molenaar; Bram De Wilde; Stephen S Roberts; Kaat Durinck; Frank Speleman
Journal:  Sci Adv       Date:  2022-07-13       Impact factor: 14.957

5.  Induced differentiation inhibits sphere formation in neuroblastoma.

Authors:  Brian T Craig; Eric J Rellinger; Alexandra L Alvarez; Haley L Dusek; Jingbo Qiao; Dai H Chung
Journal:  Biochem Biophys Res Commun       Date:  2016-06-11       Impact factor: 3.575

6.  Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.

Authors:  M Emmy M Dolman; Evon Poon; Marli E Ebus; Ilona J M den Hartog; Carel J M van Noesel; Yann Jamin; Albert Hallsworth; Simon P Robinson; Kevin Petrie; Rolf W Sparidans; Robbert J Kok; Rogier Versteeg; Huib N Caron; Louis Chesler; Jan J Molenaar
Journal:  Clin Cancer Res       Date:  2015-07-22       Impact factor: 12.531

7.  Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel.

Authors:  Esther M van Wezel; Lieke M J van Zogchel; Jalenka van Wijk; Ilse Timmerman; Ngoc-Kim Vo; Lily Zappeij-Kannegieter; Boris deCarolis; Thorsten Simon; Max M van Noesel; Jan J Molenaar; Tim van Groningen; Rogier Versteeg; Huib N Caron; C Ellen van der Schoot; Jan Koster; Johan van Nes; Godelieve A M Tytgat
Journal:  JCO Precis Oncol       Date:  2019-10-03

8.  TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation.

Authors:  Jeroen Middelbeek; Daan Visser; Linda Henneman; Alwin Kamermans; Arthur J Kuipers; Peter M Hoogerbrugge; Kees Jalink; Frank N van Leeuwen
Journal:  Oncotarget       Date:  2015-04-20

9.  Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours.

Authors:  Noémie Braekeveldt; Caroline Wigerup; David Gisselsson; Sofie Mohlin; My Merselius; Siv Beckman; Tord Jonson; Anna Börjesson; Torbjörn Backman; Irene Tadeo; Ana P Berbegall; Ingrid Ora; Samuel Navarro; Rosa Noguera; Sven Påhlman; Daniel Bexell
Journal:  Int J Cancer       Date:  2014-10-07       Impact factor: 7.396

10.  G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.

Authors:  Paula Martinez Sanz; Dieke J van Rees; Hanke L Matlung; Godelieve A M Tytgat; Katka Franke; Lieke M J van Zogchel; Bart Klein; Panagiota Bouti; Hugo Olsman; Karin Schornagel; Ivana Kok; Ali Sunak; Kira Leeuwenburg; Ilse Timmerman; Miranda P Dierselhuis; Waleed M Kholosy; Jan J Molenaar; Robin van Bruggen; Timo K van den Berg; Taco W Kuijpers
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.